EUVIMEDEUVIMED entdecken
Vergleichsstudie

Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with CKD

Mohammad Abdullah Al Zubair Naim iD, Fridtjof Thomas iD, Elani Streja iD, Robert Lowell Davis iD, Kamyar Kalantar-Zadeh iD, Keiichi Sumida, Csaba P Kovesdy

Clinical Journal of the American Society of Nephrology · 2026-11 · 21 (11) · 1914-1927

DOI: 10.2215/cjn.0000001188 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 11.08.2026. Verfasst von Mohammad Abdullah Al Zubair Naim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Renal Insufficiency, Chronic, Hypolipidemic Agents, Glomerular Filtration Rate. Die Arbeit nennt 53 Literaturangaben. Gefördert von: U.S. Department of Veterans Affairs, Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, HSR&D, VA Information Resource Center, VA Memphis and Long Beach Medical Centers.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points In this large cohort of US veterans with CKD, unlike niacin, long-term fibrate use (compared with statin use) was associated with slower eGFR decline. There was no statistically significant difference in the risk of major adverse kidney events in fibrate and niacin users compared with statin users. The potential renoprotective effects of fibrates can be particularly useful in patients with CKD who require triglyceride-lowering and HDL-elevating effects.

Background

Dyslipidemia, distinctly characterized by hypertriglyceridemia and impaired HDL cholesterol metabolism in patients with CKD, is associated with kidney disease progression. However, evidence on the renal outcomes of triglyceride-targeting lipid-lowering therapies, such as fibrates and niacin, often prescribed to patients with non–dialysis-dependent CKD, is insufficient and equivocal.

Methods

We designed this retrospective cohort study using a target trial emulation framework and leveraged data from a nationwide cohort of 3,562,882 US veterans to identify patients with incident CKD initiating de novo lipid-lowering therapies. We compared eGFR decline from baseline and the odds of rapid eGFR decline in fibrate and niacin initiators versus statin initiators using the mixed-effects model–predicted 1-, 3-, and 10-year eGFR slopes, adjusted for baseline covariates. We also compared the risk of major adverse kidney events (composite of a sustained ≥57% decrease in eGFR from baseline, sustained eGFR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsRenal Insufficiency, ChronicHypolipidemic AgentsGlomerular Filtration RateNiacinDyslipidemiasFibric AcidsTriglyceridesHumansMaleFemaleMiddle AgedAgedRetrospective StudiesTreatment OutcomeUnited States

Stichwörter der Autor:innen

CKDESKDcardiovascular diseasecohort studiesdyslipidemiaepidemiology and outcomeshypercholesterolemialipidsmortality risksurvival analysis

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsNiacinFibric AcidsTriglycerides

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
  • Division of Biostatistics, Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
  • Division of Nephrology, Hypertension, and Kidney Transplantation, Department of Medicine, University of California Irvine School of Medicine, Orange, California.
  • Department of Pediatrics, Center for Biomedical Informatics, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
  • Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, California.
  • Division of Nephrology, Hypertension, and Transplantation, Department of Medicine, Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, California.

ORCID-Profile: Mohammad Abdullah Al Zubair Naim, Fridtjof Thomas, Elani Streja, Robert Lowell Davis, Kamyar Kalantar-Zadeh

Förderung

  • U.S. Department of Veterans Affairs
  • Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, HSR&D, VA Information Resource Center
  • VA Memphis and Long Beach Medical Centers

Zitieren

APA

Naim, M. A. A. Z., Thomas, F., Streja, E., Davis, R. L., Kalantar-Zadeh, K., Sumida, K., & Kovesdy, C. P. (2026). Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with CKD. Clinical Journal of the American Society of Nephrology, 21(11), 1914-1927. https://doi.org/10.2215/cjn.0000001188

Vancouver

Naim MAAZ, Thomas F, Streja E, Davis RL, Kalantar-Zadeh K, Sumida K, et al. Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with CKD. Clinical Journal of the American Society of Nephrology. 2026;21(11):1914-1927. doi:10.2215/cjn.0000001188

BibTeX
@article{Naim2026,
  author = {Naim, Mohammad Abdullah Al Zubair and Thomas, Fridtjof and Streja, Elani and Davis, Robert Lowell and Kalantar-Zadeh, Kamyar and Sumida, Keiichi and Kovesdy, Csaba P},
  title = {Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with CKD},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {1914--1927},
  doi = {10.2215/cjn.0000001188}
}
Kostenlos starten →